BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2000

View Archived Issues

5-HT1A receptor agonist MKC-242 has antiaggressive activity in isolated mice

Read More

Ro-60-0175 exerts differential effects in combination with antidepressants in mouse model

Read More

Photofrin approved in Sweden, Ireland and Italy

Read More

Maxim submits NDA for Maxamine

Read More

Innohep approved by FDA for DVT

Read More

Arsenic trioxide receives third orphan drug designation from FDA

Read More

Nucleotides in development at Inspire for various clinical indications

Read More

Inhibitors of fungal chitin synthase a focus of research at Roche

Read More

SM-20550 provides protection against I/R-induced skeletal muscle injury

Read More

Role of vasopressin and vasopressin antagonists in heart failure reviewed at recent congress

Read More

Centaur completes enrollment in phase IIa Parkinson's disease trial

Read More

Added benefit of ET blockade and angiotensin receptor antagonism in CHF

Read More

M-Vax now available in Australia for melanoma therapy

Read More

Emivirine may be useful for preventing perinatal transmission of HIV, as reported at AIDS conference

Read More

Micrologix Biotech advances additional products into clinical trials

Read More

HIV-1 RT dimer destabilization as a target for new antiviral agents

Read More

Potent anti-HIV activity described for human lysozyme fragments at AIDS conference

Read More

Genzyme General files MAA for approval of Fabrazyme in Europe

Read More

EMEA accepts MAA for Replagal as treatment of Fabry disease

Read More

Design and characterization of low-affinity, short-acting A2A AdoR agonists

Read More

ZymoGenetics isolates new PDGF-alpha receptor-binding polypeptide

Read More

Triazolo CCR3 receptor antagonists claimed by Toray for Rx of allergic diseases, etc.

Read More

Banyu presents new heterocyclic ORL1 receptor antagonists, their preparation and use

Read More

Indena's new colchicine derivatives active against multidrug-resistant cancer cells

Read More

K-5993: a new peptide IL-4 antagonist

Read More

Novel series of antioxidants emerges from R&D at ADIR

Read More

Novel COMT inhibitors for Parkinson's disease under study at Portela

Read More

Antisense modulators of EGR-1 expression patented by Isis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing